BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 10782363)

  • 1. Management of Graves' ophthalmopathy: reality and perspectives.
    Bartalena L; Pinchera A; Marcocci C
    Endocr Rev; 2000 Apr; 21(2):168-99. PubMed ID: 10782363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.
    Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Pinchera A
    Thyroid; 1992; 2(2):171-8. PubMed ID: 1525588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graves' ophthalmopathy and 131I therapy.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
    Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating severe Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Pinchera A
    Baillieres Clin Endocrinol Metab; 1997 Oct; 11(3):521-36. PubMed ID: 9532337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Graves' ophthalmopathy.
    Wiersinga WM
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):396-404. PubMed ID: 17452966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and prevention of Graves' ophthalmopathy.
    Wiersinga WM; Bartalena L
    Thyroid; 2002 Oct; 12(10):855-60. PubMed ID: 12487767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Graves' ophthalmopathy].
    Badelon I; Morax S
    Rev Prat; 2005 Jan; 55(2):183-6. PubMed ID: 15826000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid-associated Ophthalmopathy.
    Şahlı E; Gündüz K
    Turk J Ophthalmol; 2017 Apr; 47(2):94-105. PubMed ID: 28405484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between management of hyperthyroidism and course of the ophthalmopathy.
    Bartalena L; Tanda ML; Piantanida E; Lai A; Pinchera A
    J Endocrinol Invest; 2004 Mar; 27(3):288-94. PubMed ID: 15165006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.
    Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Lepri A; Pinchera A
    J Endocrinol Invest; 1991 Nov; 14(10):853-60. PubMed ID: 1802923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy.
    Marcocci C; Marinò M
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):325-37. PubMed ID: 22632369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of thyroid eye disease.
    Bartalena L; Marcocci C; Tanda L; Pinchera A
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S458-65. PubMed ID: 12192546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graves' ophthalmopathy--a clinical review.
    Carter JN
    Aust N Z J Ophthalmol; 1990 Aug; 18(3):239-42. PubMed ID: 2261168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
    N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical management of Graves' ophthalmopathy.
    Prummel MF; Wiersinga WM
    Thyroid; 1995 Jun; 5(3):231-4. PubMed ID: 7580273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment options for Graves' orbitopathy.
    Marcocci C; Altea MA; Leo M
    Expert Opin Pharmacother; 2012 Apr; 13(6):795-806. PubMed ID: 22404364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graves' ophthalmopathy: state of the art and perspectives.
    Bartalena L; Wiersinga WM; Pinchera A
    J Endocrinol Invest; 2004 Mar; 27(3):295-301. PubMed ID: 15165007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.